AbbVie’s dual-acting myeloma drug etentamig meets main Phase 3 goal, showing longer progression-free survival

AbbVie announced that its bispecific antibody etentamig achieved the primary endpoint in a Phase 3 trial for patients with multiple myeloma who have progressed after two or more prior therapies. The study showed that participants receiving etentamig experienced a longer period without disease progression compared with those on standard treatment regimens.

The company highlighted a more favorable safety profile, noting lower rates of two serious immune‑mediated reactions that are common with similar agents from Johnson & Johnson, Pfizer and Regeneron. This reduced toxicity could lessen the need for intensive post‑treatment monitoring.

If the drug continues to demonstrate these advantages, AbbVie plans to submit it to the U.S. Food and Drug Administration later this year, positioning etentamig for use in community oncology settings where simpler safety management is valuable.